Skip to main content

Table 1 Pharmacokinetic parameters for pantoprazole, rabeprazole, and omeprazole under fasting and fed conditions. Among 71 volunteers receiving omeprazole, 35 were the same subjects. Data are expressed as mean ± standard deviation. *p ≤ 0.05 vs. men

From: Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole

 

n

AUC0-∞ (ng·h/ml)

Cmax (ng/ml)

Tmax (h)

t1/2 (h)

Vd/F (l/kg)

Cl/F (L/h·kg)

Ke

Pantoprazole (n = 81)

Fast

36

6951.4 ± 3293.2

2779.1 ± 861.6

3.0 ± 0.8

1.3 ± 0.6

0.17 ± 0.03

0.11 ± 0.04

0.61 ± 0.21

  Men

18

6584.5 ± 3832.8

2316.4 ± 580.9

3.1 ± 0.8

1.5 ± 0.7

0.18 ± 0.03

0.11 ± 0.03

0.56 ± 0.23

  Women

18

7318.4 ± 2711.6

3241.8 ± 858.8

2.9 ± 0.8

1.1 ± 0.3

0.16 ± 0.03

0.11 ± 0.05

0.65 ± 0.18

Fed

45

4633.5 ± 2022.7

2646.2 ± 603.1

7.0 ± 3.0

1.3 ± 0.6

0.26 ± 0.10

0.16 ± 0.06

0.63 ± 0.21

  Men

23

4607.8 ± 2265.1

2590.7 ± 601.2

5.6 ± 1.1

1.3 ± 0.5

0.25 ± 0.08

0.15 ± 0.07

0.61 ± 0.23

  Women

22

4660.4 ± 1787.8

2704.2 ± 613.6

8.4 ± 3.7*

1.2 ± 0.7

0.28 ± 0.12

0.17 ± 0.05

0.65 ± 0.19

Fed vs. Fast

ratio; 90% CI; p value

65.6; 55.7–77.2

p = 0.0001

93.7; 85.5–102.7

p = 0.2412

227.2; 203.2–254.1

p = 0.0001

95.3; 82.8–109.8

p = 0.5749

147.1; 134.3–161.0

p = 0.0001

151.0; 128.7–177.2

p = 0.0001

104.9; 91.1–120.7

p = 0.5749

Rabeprazole (n = 69)

Fast

35

971.9 ± 361.2

556.4 ± 176.2

3.7 ± 0.9

1.3 ± 0.5

0.60 ± 0.17

0.35 ± 0.11

0.60 ± 0.20

  Men

18

836.3 ± 313.0

479.1 ± 139.7

3.6 ± 0.9

1.2 ± 0.5

0.55 ± 0.11

0.35 ± 0.13

0.64 ± 0.20

  Women

17

1115.5 ± 361.4

638.3 ± 177.2

3.7 ± 0.9

1.4 ± 0.5

0.65 ± 0.20

0.35 ± 0.10

0.56 ± 0.20

Fed

34

1047.3 ± 382.3

675.8 ± 218.8

7.2 ± 2.6

2.2 ± 1.3

0.91 ± 0.45

0.34 ± 0.18

0.42 ± 0.22

  Men

19

1045.8 ± 361.49

634.6 ± 144.8

6.9 ± 3.0

2.3 ± 1.3

0.91 ± 0.52

0.31 ± 0.18

0.38 ± 0.17

  Women

15

1049.2 ± 420.3

727.9 ± 284.0

7.6 ± 2.0

2.0 ± 1.3

0.92 ± 0.37

0.38 ± 0.18

0.48 ± 0.27

Fed vs. Fast

ratio; 90% CI; p value

106.7; 91.3–124.8

p = 0.4886

121.3; 106.9–137.6

p = 0.0132

191.5; 172.2–212.9

p = 0.0001

153.1; 126.9–184.7

p = 0.0003

144.3; 125.6–165.9

p = 0.0001

93.1; 79.5–109.1

p = 0.4531

65.3; 54.1–78.8

p = 0.0003

Omeprazole (n = 36)

Fast

35

2190.8 ± 2011.5

930.9 ± 434.6

2.0 ± 0.7

1.1 ± 0.6

0.64 ± 0.34

0.53 ± 0.38

0.76 ± 0.29

  Men

17

2375.9 ± 2480.1

858.8 ± 432.6

2.1 ± 0.7

1.3 ± 0.8

0.65 ± 0.38

0.50 ± 0.44

0.70 ± 0.29

  Women

18

2016.0 ± 1495.4

999.1 ± 437.7

1.9 ± 0.6

1.0 ± 0.4

0.63 ± 0.31

0.56 ± 0.34

0.82 ± 0.29

Fed

36#

1928.3 ± 1878.5

682.6 ± 394.1

4.9 ± 1.1

1.3 ± 0.6

1.02 ± 1.07

0.64 ± 0.55

0.67 ± 0.32

  Men

18

2135.8 ± 2282.7

725.0 ± 447.6

4.5 ± 0.9

1.3 ± 0.7

0.75 ± 0.52

0.57 ± 0.49

0.69 ± 0.35

  Women

18

1720.9 ± 1402.0

640.2 ± 640.1

5.4 ± 1.0

1.3 ± 0.5

1.30 ± 1.38

0.73 ± 0.61

0.65 ± 0.30

Fed vs. Fast

ratio; 90% CI; p value

86.2; 81.2–91.6

p = 0.0002

63.0; 55.0–72.2

p = 0.0001

262.5; 232.6–296.2

p = 0.0001

117.6; 105.6–130.9

p = 0.0156

136.1; 105.6–130.9

p = 0.0029

116.1; 108.7–124.1

p = 0.0006

85.0; 76.4–94.7

p = 0.0156

  1. #35 of the subjects participated in both fast and fed omeprazole clinical trials